Clinical trial
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic…
NCT00006108 · UNC Lineberger Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006108 |
|---|---|
| Title | Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase II Trial of Xeloda, Every Three Week Taxol and Herceptin in Metastatic Breast Cancer |
| Lead sponsor | UNC Lineberger Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, capecitabine, paclitaxel |
| Start date | Aug 1, 1999 |
| Primary completion | Sep 1, 2001 |
| Completion | Jul 1, 2002 |
| First posted | Feb 26, 2004 |
| Last update posted | Feb 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: